Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

Journal article

Open access

Peer reviewed

David SHACKELFORD, Candia KENIFIC, Agnieszka BLUSZTAJN, Samuel WAXMAN and RUIBAO RUIBAO REN

Cancer research (Chicago, Ill.), Vol.66(23), pp.11360-11369

2006

PMID: 17145882

Abstract

Biological and medical sciences

Medical sciences

Antineoplastic agents

Pharmacology. Drug treatments

Tumors

url

https://doi.org/10.1158/0008-5472.CAN-06-1774View

Published (Version of record) Open

39 Record Views

Title: Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide
Creators: David SHACKELFORD - Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts, United States
Candia KENIFIC - Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts, United States
Agnieszka BLUSZTAJN - Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts, United States
Samuel WAXMAN - Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York, United States
RUIBAO RUIBAO REN - Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts, United States
Publication Details: Cancer research (Chicago, Ill.), Vol.66(23), pp.11360-11369
Publisher: American Association for Cancer Research; Philadelphia, PA
Identifiers: 9923958111601921
Academic Unit: Rosenstiel Basic Medical Sciences Research Center; Department of Biology
Language: English
Resource Type: Journal article